Colorectal cancer statistics, 2020

Siegel, Rebecca L.; Miller, Kimberly D.; Sauer, Ann Goding; Fedewa, Stacey A.; Butterly, Lynn F.; Anderson, Joseph C.; Cercek, Andrea; Smith, Robert A.; Jemal, Ahmedin

doi:10.3322/caac.21601

Cited by 4,444 publications

(3,865 citation statements)

References 91 publications

Supporting

Mentioning

3,773

Contrasting

Unclassified

Order By: Relevance

“…21 CRC incidence and mortality rates have been declining for the past 2 decades among adults aged 50 years and older, which is largely attributable to the contribution of screening to prevention and early detection. 46 Among people aged 50 years and older, CRC incidence declined by 32% between 2000 and 2013, and CRC mortality has declined by 34% between 2000 and 2014, although, as described below, mortality has increased among those younger than 50 years, which is attributable to the rising incidence of CRC in successive age cohorts born between 1950 and 1990. 47 CRC incidence and mortality also remain higher in blacks than any other racial/ ethnic group, with incidence rates 20% higher and mortality rates 40% greater in blacks than in non-Hispanic whites.…”

Section: Screening and Surveillance For The Early Detection Of Adenommentioning

confidence: 99%

“…47 CRC incidence and mortality also remain higher in blacks than any other racial/ ethnic group, with incidence rates 20% higher and mortality rates 40% greater in blacks than in non-Hispanic whites. 48 The ACS updated its guideline for CRC screening in individuals at average risk in 2018. The ACS recommends that adults aged 45 years and older with an average risk of CRC undergo regular screening with either a high-sensitivity stool-based test or a structural (visual) exam, depending on patient preference and test availability.…”

Section: Screening and Surveillance For The Early Detection Of Adenommentioning

confidence: 99%

See 1 more Smart Citation

Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening

Smith

Andrews

Brooks

et al. 2018

CA A Cancer J Clinicians

Self Cite

444

319

View full text Add to dashboard Cite

Each year, the American Cancer Society publishes a summary of its guidelines for early cancer detection, data and trends in cancer screening rates from the National Health Interview Survey, and select issues related to cancer screening. In this 2018 update, we also summarize the new American Cancer Society colorectal cancer screening guideline and include a clarification in the language of the 2013 lung cancer screening guideline. CA Cancer J Clin 2018;68:297-316. © 2018 American Cancer Society.

show abstract

Section: Screening and Surveillance For The Early Detection Of Adenommentioning

confidence: 99%

Section: Screening and Surveillance For The Early Detection Of Adenommentioning

confidence: 99%

Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening

Smith

Andrews

Brooks

et al. 2018

CA A Cancer J Clinicians

Self Cite

444

319

View full text Add to dashboard Cite

show abstract

“…1 CRC disease burden varies across racial groups, with the highest incidence and mortality rates in blacks, American Indians, and Alaska Natives. 2 Temporal trends in CRC incidence and mortality among adults aged 55 years and older have shown a decline for several decades that accelerated around 2000, particularly among adults aged 65 years and older. 2,3 Although changes in exposure to risk factors account for an estimated one-half of the reduction in incidence and one-third of the reduction in mortality before 2000, subsequent accelerated declines in incidence and mortality since 2000 are largely attributable to increased uptake of screening, with improved treatment also contributing to mortality reductions.…”

Section: Introductionmentioning

confidence: 99%

“…2 Temporal trends in CRC incidence and mortality among adults aged 55 years and older have shown a decline for several decades that accelerated around 2000, particularly among adults aged 65 years and older. 2,3 Although changes in exposure to risk factors account for an estimated one-half of the reduction in incidence and one-third of the reduction in mortality before 2000, subsequent accelerated declines in incidence and mortality since 2000 are largely attributable to increased uptake of screening, with improved treatment also contributing to mortality reductions. [3][4][5][6] In contrast, among adults younger than 55 years, there was a 51% increase in the incidence of CRC from 1994 to 2014 and an 11% increase in mortality from 2005 to 2015.…”

Section: Introductionmentioning

confidence: 99%

Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society

Wolf

Fontham

Church

et al. 2018

CA A Cancer J Clinicians

Self Cite

1,499

1,108

View full text Add to dashboard Cite

In the United States, colorectal cancer (CRC) is the fourth most common cancer diagnosed among adults and the second leading cause of death from cancer. For this guideline update, the American Cancer Society (ACS) used an existing systematic evidence review of the CRC screening literature and microsimulation modeling analyses, including a new evaluation of the age to begin screening by race and sex and additional modeling that incorporates changes in US CRC incidence. Screening with any one of multiple options is associated with a significant reduction in CRC incidence through the detection and removal of adenomatous polyps and other precancerous lesions and with a reduction in mortality through incidence reduction and early detection of CRC. Results from modeling analyses identified efficient and model-recommendable strategies that started screening at age 45 years. The ACS Guideline Development Group applied the Grades of Recommendations, Assessment, Development, and Evaluation (GRADE) criteria in developing and rating the recommendations. The ACS recommends that adults aged 45 years and older with an average risk of CRC undergo regular screening with either a high-sensitivity stool-based test or a structural (visual) examination, depending on patient preference and test availability. As a part of the screening process, all positive results on noncolonoscopy screening tests should be followed up with timely colonoscopy. The recommendation to begin screening at age 45 years is a qualified recommendation. The recommendation for regular screening in adults aged 50 years and older is a strong recommendation. The ACS recommends (qualified recommendations) that: 1) average-risk adults in good health with a life expectancy of more than 10 years continue CRC screening through the age of 75 years; 2) clinicians individualize CRC screening decisions for individuals aged 76 through 85 years based on patient preferences, life expectancy, health status, and prior screening history; and 3) clinicians discourage individuals older than 85 years from continuing CRC screening. The options for CRC screening are: fecal immunochemical test annually; high-sensitivity, guaiac-based fecal occult blood test annually; multitarget stool DNA test every 3 years; colonoscopy every 10 years; computed tomography colonography every 5 years; and flexible sigmoidoscopy every 5 years. CA Cancer J Clin 2018;68:250-281. © 2018 American Cancer Society.

show abstract

“…Although pancreatic cancer is not the most frequent cancer, its survival rate closely parallels its incidence rate. 1,2 Main reasons for the low survival rate are late diagnosis and limited curative treatments. Nowadays, surgical resection, chemotherapy and radiotherapy are the mainstays of treatments for pancreatic cancer, among which surgical resection is the only potentially curative treatment.…”

Section: Introductionmentioning

confidence: 99%

Propofol inhibits pancreatic cancer proliferation and metastasis by up‐regulating miR‐328 and down‐regulating ADAM8

Gao

Zhang

2019

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Propofol is commonly used for anaesthesia during surgery, and accumulating evidence has demonstrated that propofol is associated with tumour suppression. For example, propofol down‐regulates the expression of vascular endothelial growth factor to inhibit pancreatic cancer malignancy. However, deeper insights into its underlying mechanism are needed. In this study, we treated pancreatic cell lines Panc1 and Bxpc3 with or without propofol. Cell proliferation, migration and invasion were evaluated using 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide and transwell assays. Real‐time polymerase chain reaction was used to measure RNA expression levels. Luciferase assay was performed to determine the transcriptional activity of microRNAs (miRNAs). We found that propofol significantly reduced the proliferation, migration and invasion of pancreatic cancer cells compared to untreated cells. By testing the changes in miRNAs after propofol treatment, propofol was shown to strikingly enhance the expression of miR‐328. Luciferase assays demonstrated that propofol repressed the transcriptional activity of miR‐328, while a disintegrin and metalloproteinase 8 (ADAM8) was a direct target of miR‐328. Knockdown of miR‐328 or ADAM8 led to significantly decreased cell growth and viability. Our results implicate that propofol inhibits pancreatic cancer growth and metastasis by enhancing miR‐328 which targets ADAM8.

show abstract

Colorectal cancer statistics, 2020

Cited by 4,444 publications

References 91 publications

Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening

Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening

Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society

Propofol inhibits pancreatic cancer proliferation and metastasis by up‐regulating miR‐328 and down‐regulating ADAM8

Contact Info

Product

Resources

About